Nautilus Capital

Solana Powers 24/7 Tokenized Stock Trading: Bridging TradFi and DeFi

Solana now processes over $3.5 billion in tokenized stock trades each month, cementing its position as the leading blockchain for on-chain equity markets.

Read

Macro• 7 min

Is AI a Bubble or Breakthrough? Analyzing Recession Risk in Tech

Is the current AI frenzy a revolutionary breakthrough or a speculative bubble destined to pop? We dive into the macro indicators, valuation metrics, and supply chain risks.

Read

Macro• 4 min

The Billion-Dollar Play: Economics Behind NBA Sports Betting

Explore the economic powerhouse of the NBA, where sports betting partnerships are driving record valuations and transforming revenue streams in the wake of PASPA's repeal.

Read

Newsroom• April 16, 2026

Private Equity’s Next Act: Liquidity, Brand, and the Trillion-Dollar Wealth Opportunity

Private equity is evolving beyond buyouts into a $25 trillion ecosystem. We explore the massive untapped wealth channel, the rise of private credit, and the liquidity revolution reshaping alternative assets.

Read

Stocks• April 16, 2026

Why BlackRock’s Ethereum ETF Could Be the Decade’s Biggest Trade

BlackRock’s ETHA has surpasssed $10 billion in AUM, fueled by institutional demand and the GENIUS Act. With rising global liquidity and a potential move to $16,000, we analyze why Ethereum is the decade's biggest trade.

Read

Stocks• April 16, 2026

FUNDSTRAT GRANNY SHOTS US LARGE CAP: High-Conviction Thematic Investing

Fundstrat’s GRNY ETF combines a top-down fundamental research framework with a quantitative, bottom-up stock selection process. We dive into the seven core themes driving its massive outperformance against the S&P 500.

Read

Stocks• April 16, 2026

Peloton: The Netflix of Fitness or a Subscription Gamble?

Peloton has transformed from a volatile, hardware-driven business into a durable, profitable subscription model. We deconstruct the $55 habit with software-like margins.

Read

Stocks• April 16, 2026

Viking Therapeutics: Undervalued Leader in the Next Obesity Drug Revolution

Viking Therapeutics is emerging as a top contender in the trillion-dollar obesity market. With superior Phase 2 data for its oral pill VK2735 and strong buyout potential, we explore why this biotech is deeply undervalued.

Read